Acalabrutinib + Rituximab (continuous BTKi + R)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ACALABRUTINIB` `DRUG-RITUXIMAB`

ID	`REG-ACALABRUTINIB-RITUXIMAB`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Notes

1L for unfit / older MCL (age >65 OR ECOG ≥2 OR transplant-ineligible) AND for TP53-mutant / blastoid / high-risk where chemoimmuno fails. SHINE trial showed BTKi+R+chemo modestly superior to chemo alone in older fit; access constraints in Ukraine push toward BTKi+R simpler.

Used By

Indication

IND-MCL-1L-BTKI-R - IND-MCL-1L-BTKI-R
IND-MCL-1L-INTENSIVE - IND-MCL-1L-INTENSIVE

Regimen

REG-MCL-INTENSIVE-RDHAP-AUTOSCT - MCL: alternating R-CHOP/R-DHAP induction followed by an ASCT pathway (MCL Younger-based)